Objectif The scope of the project is to generate a candidate drug targeting the inflammatory mediator High mobility group box 1 protein (HMGB1) to be used in treatment of stroke. The candidate drug will be validated in animal models, characterized and optimized for subsequent clinical development.Stroke remains a leading cause of death and disability throughout the world. Within EU, more than 500 000 persons die of stroke each year. Of those surviving stroke, 50% are left with physical or cognitive impairment and the total annual cost of stroke is estimated at Euro 27 billion.Stroke occurs as a consequence of hemorrhagic insult or artery occlusion due to underlying cardiovascular disease. Pivotal in beneficial treatment of stroke is instant intervention. Blood clot dissolution using recombinant tissue plasminogen activator is the only pharmacological treatment demonstrated to limit neurological damage in stroke, but is only effective for patients who present within 3 hours after stroke onset. Thus there is an unmet need for an efficacious therapy that can be administered within and beyond 3 hours to achieve neuroprotection. HMGB1, released during the cerebral ischemic event and the subsequent neuroinflammation, is a well-characterized mediator of inflammation. Beneficial effects of blocking HMGB1 is proven in preclinical stroke studies. The drug to be developed is an Affibody molecule binding to and neutralizing HMGB1. Affibody molecules are engineered proteins significantly smaller than antibodies and therefore having favorable biodistribution properties, and a history of being efficient and non-toxic in clinical trials. In this application, we describe a multidisciplinary research consortium with Europe´s leading scientists in HMGB1 research and in registry-based clinical trial and dissemination methodology. The consortium has unique potentials to bring a new treatment principle against cerebral stroke to clinical reality. Champ scientifique humanitieshistory and archaeologyhistorynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurologystroke Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.4.2-1 - Discovery research to reveal novel targets for cardiovascular disease treatment Appel à propositions FP7-HEALTH-2013-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur KAROLINSKA INSTITUTET Contribution de l’UE € 1 061 198,40 Adresse Nobels Vag 5 17177 Stockholm Suède Voir sur la carte Région Östra Sverige Stockholm Stockholms län Type d’activité Higher or Secondary Education Establishments Contact administratif Caroline Hamilton (Mrs.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (5) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire AFFIBODY AB Suède Contribution de l’UE € 3 121 291,00 Adresse GUNNAR ASPLUNDS ALLE 24 171 63 Solna Voir sur la carte Région Östra Sverige Stockholm Stockholms län Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Fredrik Frejd (Prof.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée HMGBIOTECH SRL Italie Contribution de l’UE € 576 712,00 Adresse PIAZZALE GORINI PAOLO 8 20133 Milano Voir sur la carte Région Nord-Ovest Lombardia Milano Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Maura Casalgrandi (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée THE UNIVERSITY OF LIVERPOOL Royaume-Uni Contribution de l’UE € 396 562,00 Adresse BROWNLOW HILL 765 FOUNDATION BUILDING L69 7ZX Liverpool Voir sur la carte Région North West (England) Merseyside Liverpool Type d’activité Higher or Secondary Education Establishments Contact administratif Daniel Antoine (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITA VITA-SALUTE SAN RAFFAELE Italie Contribution de l’UE € 454 073,60 Adresse VIA OLGETTINA 58 20132 Milano Voir sur la carte Région Nord-Ovest Lombardia Milano Type d’activité Higher or Secondary Education Establishments Contact administratif Maria Rosa Pedrazzi (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée CHARITE - UNIVERSITAETSMEDIZIN BERLIN Allemagne Contribution de l’UE € 379 794,00 Adresse Chariteplatz 1 10117 Berlin Voir sur la carte Région Berlin Berlin Berlin Type d’activité Higher or Secondary Education Establishments Contact administratif Karen Gertz (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
